Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TSHA-101

Gene therapy (AAV vector) · Gene replacement

Phase 1/2 Most advanced trial
1 Registered trials

What is TSHA-101?

TSHA-101 is an AAV9 viral vector carrying the HEXA and HEXB genes, delivered by intrathecal injection. It is being studied in infantile GM2 gangliosidosis, including Tay-Sachs and Sandhoff disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Neurology
In trials of
TSHA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04798235 Phase 1/2 Infantile GM2 Gangliosidosis (Disorder) Active not recruiting TSHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Infantile GM2 Gangliosidosis (Disorder)

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.